The study of testing effect of syp.Rubyclin in discoloration and itching of skin

An Open Label,Prospective,Phase II,Clinical study to Evaluate Efficacy and safety of syp.Rubyclin in the Eczema.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012718

Enrollment

Registered

2018-03-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Eczema skin disorders redness itching burning

Interventions

Intervention1: Syp Rubyclin: 20 ml twice daily with water days after meal for 30 days Control Intervention1: Not applicable: Notapplicable

Eligibility

Inclusion criteria

Inclusion criteria: subjects with inflammation redness itching burning in eczema

Exclusion criteria

Exclusion criteria: Subjects with Diabetes Mellitus Type I and uncontrolled Diabetes Mellitus Type II. Known subjects of abnormal thyroid function. Known cases of Severe/Chronic Hepatic or Renal disease. Known subject of any active malignancy. Subjects giving history of significant cardiovascular event

Design outcomes

Primary

Measure	Time frame
To study the effect of syp rubyclin in the eczema bacterial count of infected lesion 10 days scaling inflammation burning and itching in eczema Timepoint: 30 days	—

Secondary

Measure	Time frame
Reduction severity of pruritis in eczema eczema severity grade on IGA scaleTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDrSanjivani Jadhav

Ayurved Seva Sanghs Ayurved Mahavidyalaya Nashik

rnitin848@gmail.com9623059379

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026